Category: <span>MTG Biotherapeutics</span>

Category: MTG Biotherapeutics

anti-CTLA-4, Anti-PD-1, Anti-PD-L1, Apoptosis, Dickkpf-3, FDA, Hypermethylation, Immuno-oncology, Immunotherapy, Mesothelioma News, MTG Biotherapeutics, MTG-201, Okayama Medical Hospital, Orphan Drug Designation, Premetrexed, Reduced Expression in Immortalized Cells, REIC, Rob Lowenthal, T-cell lymphocytes, US Food and Drug Administration

New Mesothelioma Treatment Receives FDA Orphan Drug Designation

 

A new drug has been granted Orphan Drug Status by the US FDA as a potentially safe and effective treatment for mesothelioma cancer.